Customize prx-10 Antibody

Description

Peroxiredoxin (PRX) Antibodies

Peroxiredoxins are a family of antioxidant enzymes (PRX I-VI) that regulate oxidative stress. Antibodies targeting PRX isoforms include:

PRX Antibody (B-11)

Target: Recognizes multiple PRX isoforms (I, II, III, IV, V, VI) across species (human, mouse, rat) .
Applications:
- Western blot (1:2000 dilution)
- Immunohistochemistry (1:150 dilution)
- ELISA, immunoprecipitation, immunofluorescence .
Clinical Relevance:
- Overexpressed PRX I/II linked to Alzheimer’s disease and Down syndrome .
- PRX I implicated in breast cancer progression .

PRRX1 Antibody (OTI1E10)

Target: Paired related homeobox 1 (PRRX1), a transcription factor .
Applications:
- Western blot (1:2000 dilution)
- Immunohistochemistry (1:150 dilution) .

PRX-102 (Pegunigalsidase-alfa)

Structure: PEGylated α-galactosidase A enzyme for Fabry disease .
Key Findings:

Parameter PRX-102 vs. Agalsidase-beta
Serum half-life (AUC) 7.6-fold higher
Anti-AGAL antibody impact 33% residual activity vs. 5%
Anti-PEG antibody impact No significant stability loss

Parameter	PRX-102 vs. Agalsidase-beta
Serum half-life (AUC)	7.6-fold higher
Anti-AGAL antibody impact	33% residual activity vs. 5%
Anti-PEG antibody impact	No significant stability loss

PRX002/RG7935

Target: Aggregated α-synuclein in Parkinson’s disease .
Clinical Data:
- Half-life: ~10.2 days in serum .
- CSF penetration: 0.3% of serum concentration .

CXCL10 Antibody Studies

While unrelated to PRX, CXCL10 antibodies (e.g., 1B6, 1F11) demonstrate structure-function insights:

1F11: Linear pharmacokinetics (half-life: 12 days) .
1B6: Non-linear clearance, dose-dependent stability .

Anti-PEG Antibodies

Prevalence: 33% of Fabry patients exhibit low anti-PEG antibodies .
Impact on PRX-102: Minimal inhibition due to low titers .

Product Specs

Buffer

Preservative: 0.03% ProClin 300; Constituents: 50% Glycerol, 0.01M PBS, pH 7.4

Form

Liquid

Lead Time

14-16 weeks lead time (made-to-order)

Synonyms

prx-10 antibody; C34E10.4 antibody; Putative peroxisomal biogenesis factor 10 antibody; Peroxin-10 antibody

Target Names

prx-10

Uniprot No.

C0HKD7

Target Background

Function

This antibody targets a protein potentially involved in peroxisomal protein import and lipid storage regulation, likely through its function within peroxisomes.

Database Links

KEGG: cel:CELE_C34E10.4

UniGene: Cel.23360

Protein Families

Pex2/pex10/pex12 family

Subcellular Location

Peroxisome membrane; Single-pass membrane protein.

Q&A

Here’s a structured collection of FAQs tailored for academic researchers working with PRX-10 antibodies, based on scientific rigor and methodological depth:

Advanced Research Questions

How do discrepancies arise between in vitro and in vivo PRX-10 antibody functionality?

Analysis Framework:
- Compare antibody binding kinetics (e.g., surface plasmon resonance) in purified protein vs. cellular lysates.
- Evaluate post-translational modifications (e.g., phosphorylation) in vivo that may alter epitope accessibility .
- Use fluorescently tagged PRX-10 to track antibody binding dynamics in live-cell imaging .

What strategies resolve contradictory data on PRX-10’s role in oxidative stress pathways?

Factor	Consideration	Validation Method
Cell type variability	PRX-10 expression varies by tissue (e.g., high in liver).	RNA-seq/proteomic profiling .
Redox state	Antibody binding may depend on PRX-10’s oligomeric state.	Non-reducing SDS-PAGE + western blot.
Compensatory isoforms	PRX VI may mask PRX-10 knockdown effects.	Dual knockout models .

How can computational modeling improve PRX-10 antibody engineering for specific epitopes?

Design Workflow:
- Use molecular docking simulations to predict antibody-antigen interactions.
- Apply phage display libraries to select variants with enhanced affinity for redox-sensitive regions .
- Validate designs using competitive inhibition assays and hydrogen peroxide scavenging assays .

Data Interpretation Challenges

Why do PRX-10 antibody-based assays show variability in neurodegenerative disease models?

Key Variables:
- Temporal changes in PRX-10 expression during disease progression (e.g., Alzheimer’s vs. Parkinson’s ).
- Interaction with pathological aggregates (e.g., α-synuclein in Parkinson’s ).
- Standardize sample preparation to minimize oxidative artifacts during tissue processing .

Methodological Best Practices

Always include isotype controls and secondary antibody-only conditions to rule out non-specific binding.
For functional studies, pair PRX-10 antibodies with activity assays (e.g., thioredoxin-coupled peroxidase assays ).
Use longitudinal sampling in vivo to account for dynamic changes in PRX-10 expression under oxidative stress .

Quick Inquiry

Personal Email Detected

Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *

Name*

Email*

Phone

Country

Source

Quantity&Size*

Product Name

Message

prx-10 Antibody